Advertisement

Psychopharmacology

, Volume 235, Issue 1, pp 71–82 | Cite as

Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence

  • Jennifer T. Lamberts
  • Lisa D. Rosenthal
  • Emily M. Jutkiewicz
  • John R. Traynor
Original Investigation

Abstract

Rationale

The use of morphine and other opioids for chronic pain is limited by the development of analgesic tolerance and physical dependence. Morphine produces its effects by activating the μ opioid receptor, which couples to Gαi/o-containing heterotrimeric G proteins. Evidence suggests that the antinociceptive effects of morphine are mediated by Gαo. However, the role of Gαo in the development of morphine tolerance and dependence is unknown.

Objective

The objective of the study is to evaluate the contribution of Gαo to the development of morphine tolerance and dependence in mice.

Methods

129S6 mice lacking one copy of the Gαo gene (Gαo +/−) were administered morphine acutely or chronically. Mice were examined for tolerance to the antinociceptive action of morphine using the 52 °C hot plate as the nociceptive stimulus and for dependence by evaluating the severity of naltrexone-precipitated withdrawal. Wild-type littermates of the Gαo +/− mice were used as controls. Changes in μ receptor number and function were determined in midbrain and hindbrain homogenates using radioligand binding and μ agonist-stimulated [35S]GTPγS binding, respectively.

Results

Following either acute or chronic morphine treatment, all mice developed antinociceptive tolerance and physical dependence, regardless of genotype. With chronic morphine treatment, Gαo +/− mice developed tolerance faster and displayed more severe naltrexone-precipitated withdrawal in some behaviors than did wild-type littermates. Morphine tolerance was not associated with changes in μ receptor number or function in brain homogenates from either wild-type or Gαo +/− mice.

Conclusions

These data suggest that the guanine nucleotide binding protein Gαo offers some protection against the development of morphine tolerance and dependence.

Keywords

Antinociception G protein Morphine μ receptor Receptor binding Tolerance Withdrawal 

Notes

Acknowledgements

This work was supported by R01 DA035316. JTL was supported by a pre-doctoral fellowship from the PhRMA Foundation and by training grants DA007267 and GM007767. The authors wish to acknowledge Claire Meurice, Joe Guel, and Jasmine Schimmel for technical support and animal care.

Compliance with ethical standards

All protocols were approved by the University of Michigan Committee on the Use and Care of Animals and experiments were performed in accordance with the Guide for the Care and Use of Laboratory Animals as adopted by the National Institutes of Health.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Bagley EE, Chieng BC, Christie MJ, Connor M (2005a) Opioid tolerance in periaqueductal gray neurons isolated from mice chronically treated with morphine. Br J Pharmacol 146:68–76CrossRefPubMedPubMedCentralGoogle Scholar
  2. Bagley EE, Gerke MB, Vaughan CW, Hack SP, Christie MJ (2005b) GABA transporter currents activated by protein kinase A excite midbrain neurons during opioid withdrawal. Neuron 45:433–445CrossRefPubMedGoogle Scholar
  3. Bryant CD, Roberts KW, Byun JS, Fanselow MS, Evans CJ (2006) Morphine analgesic tolerance in 129P3/J and 129S6/SvEv mice. Pharmacol Biochem Behav 85:769–779CrossRefPubMedPubMedCentralGoogle Scholar
  4. Buntin-Mushock C, Phillip L, Moriyama K, Palmer PP (2005) Age-dependent opioid escalation in chronic pain patients. Anesth Analg 100:1740–1745CrossRefPubMedGoogle Scholar
  5. Christie MJ (2008) Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br J Pharmacol 154:384–396CrossRefPubMedPubMedCentralGoogle Scholar
  6. Contet C, Filliol D, Matifas A, Kieffer BL (2008) Morphine-induced analgesic tolerance, locomotor sensitization and physical dependence do not require modification of mu opioid receptor, cdk5 and adenylate cyclase activity. Neuropharmacology 54:475–486CrossRefPubMedGoogle Scholar
  7. Crain SM, Shen K (2000) Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: evidence for a deficiency in GM1 ganglioside-regulated excitatory opioid receptor functions. Brain Res 856:227–235CrossRefPubMedGoogle Scholar
  8. Divin MF, Ko MC, Traynor JR (2008) Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naive and morphine-dependent mice. Eur J Pharmacol 583:48–55CrossRefPubMedPubMedCentralGoogle Scholar
  9. Duan SZ, Christe M, Milstone DS, Mortensen RM (2007) Go but not Gi2 or Gi3 is required for muscarinic regulation of heart rate and heart rate variability in mice. Biochem Biophys Res Commun 357:139–143CrossRefPubMedPubMedCentralGoogle Scholar
  10. Eitan S, Bryant CD, Saliminejad N, Yang YC, Vojdani E, Keith D, Polakiewicz R, Evans CJ (2003) Brain region-specific mechanisms for acute morphine-induced mitogen-activated protein kinase modulation and distinct patterns of activation during analgesic tolerance and locomotor sensitization. J Neurosci 23:8360–8369CrossRefPubMedGoogle Scholar
  11. Elliott J, Guo L, Traynor JR (1997) Tolerance to mu-opioid agonists in human neuroblastoma SH-SY5Y cells as determined by changes in guanosine-5′-O-(3-[35S]-thio)triphosphate binding. Br J Pharmacol 121:1422–1428CrossRefPubMedPubMedCentralGoogle Scholar
  12. Fabian G, Bozo B, Szikszay M, Horvath G, Coscia CJ, Szucs M (2002) Chronic morphine-induced changes in mu-opioid receptors and G proteins of different subcellular loci in rat brain. J Pharmacol Exp Ther 302:774–780CrossRefPubMedGoogle Scholar
  13. Farrell M (1994) Opiate withdrawal. Addiction 89:1471–1475CrossRefPubMedGoogle Scholar
  14. Fyfe LW, Cleary DR, Macey TA, Morgan MM, Ingram SL (2010) Tolerance to the antinociceptive effect of morphine in the absence of short-term presynaptic desensitization in rat periaqueductal gray neurons. J Pharmacol Exp Ther 335:674–680CrossRefPubMedPubMedCentralGoogle Scholar
  15. Gainetdinov RR, Premont RT, Bohn LM, Lefkowitz RJ, Caron MG (2004) Desensitization of G protein-coupled receptors and neuronal functions. Annu Rev Neurosci 27:107–144CrossRefPubMedGoogle Scholar
  16. Garzon J, Sanchez-Blazquez P (2001) Administration of myr(+)-G(i2)alpha subunits prevents acute tolerance (tachyphylaxis) to mu-opioid effects in mice. Neuropharmacology 40:560–569CrossRefPubMedGoogle Scholar
  17. Georgescu D, Zachariou V, Barrot M, Mieda M, Willie JT, Eisch AJ, Yanagisawa M, Nestler EJ, DiLeone RJ (2003) Involvement of the lateral hypothalamic peptide orexin in morphine dependence and withdrawal. J Neurosci 23:3106–3111CrossRefPubMedGoogle Scholar
  18. Gintzler AR, Chakrabarti S (2006) Post-opioid receptor adaptations to chronic morphine; altered functionality and associations of signaling molecules. Life Sci 79:717–722CrossRefPubMedGoogle Scholar
  19. Hao S, Liu S, Zheng X, Zheng W, Ouyang H, Mata M, Fink DJ (2011) The role of TNFalpha in the periaqueductal gray during naloxone-precipitated morphine withdrawal in rats. Neuropsychopharmacology 36:664–676CrossRefPubMedGoogle Scholar
  20. Huang W, Manglik A, Venkatakrishnan AJ, Laeremans T, Feinberg EN, Sanborn AL, Kato HE, Livingston KE, Thorsen TS, Kling RC, Granier S, Gmeiner P, Husbands SM, Traynor JR, Weis WI, Steyaert J, Dror RO, Kobilka BK (2015) Structural insights into μ-opioid receptor activation. Nature 524:315–321CrossRefPubMedPubMedCentralGoogle Scholar
  21. Ingram SL, Macey TA, Fossum EN, Morgan MM (2008) Tolerance to repeated morphine administration is associated with increased potency of opioid agonists. Neuropsychopharmacology 33:2494–2504CrossRefPubMedGoogle Scholar
  22. Kest B, Lee CE, McLemore GL, Inturrisi CE (1996) An antisense oligodeoxynucleotide to the delta opioid receptor (DOR-1) inhibits morphine tolerance and acute dependence in mice. Brain Res Bull 39:185–188CrossRefPubMedGoogle Scholar
  23. Kest B, Hopkins E, Palmese CA, Chen ZP, Mogil JS, Pintar JE (2001) Morphine tolerance and dependence in nociceptin/orphanin FQ transgenic knock-out mice. Neuroscience 104:217–222CrossRefPubMedGoogle Scholar
  24. Kest B, Hopkins E, Palmese CA, Adler M, Mogil JS (2002a) Genetic variation in morphine analgesic tolerance: a survey of 11 inbred mouse strains. Pharmacol Biochem Behav 73:821–828CrossRefPubMedGoogle Scholar
  25. Kest B, Palmese CA, Hopkins E, Adler M, Juni A, Mogil JS (2002b) Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 115:463–469CrossRefPubMedGoogle Scholar
  26. Kest B, Smith SB, Schorscher-Petcu A, Austin JS, Ritchie J, Klein G, Rossi GC, Fortin A, Mogil JS (2009) Gnao1 (G alphaO protein) is a likely genetic contributor to variation in physical dependence on opioids in mice. Neuroscience 162:1255–1264CrossRefPubMedGoogle Scholar
  27. Kolesnikov Y, Jain S, Wilson R, Pasternak GW (1998) Lack of morphine and enkephalin tolerance in 129/SvEv mice: evidence for a NMDA receptor defect. J Pharmacol Exp Ther 284:455–459PubMedGoogle Scholar
  28. Kosten TR, George TP (2002) The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect 1:13–20CrossRefPubMedPubMedCentralGoogle Scholar
  29. Lamberts JT, Jutkiewicz EM, Mortensen RM, Traynor JR (2011) Mu-opioid receptor coupling to galpha(o) plays an important role in opioid antinociception. Neuropsychopharmacology 36:2041–2053CrossRefPubMedPubMedCentralGoogle Scholar
  30. Lamberts JT, Smith CE, Li MH, Ingram SL, Neubig RR, Traynor JR (2013) Differential control of opioid antinociception to thermal stimuli in a knock-in mouse expressing regulator of G-protein signling-insensitive Gαo protein. J Neurosci 33:4369–4377CrossRefPubMedPubMedCentralGoogle Scholar
  31. Law PY, Wong YH, Loh HH (2000) Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol 40:389–430CrossRefPubMedGoogle Scholar
  32. Lester PA, Traynor JR (2006) Comparison of the in vitro efficacy of mu, delta, kappa and ORL1 receptor agonists and non-selective opioid agonists in dog brain membranes. Brain Res 1073-1074:290–296CrossRefPubMedGoogle Scholar
  33. Levitt ES, Lauren C, Purington LC, Traynor JR (2011) Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot. Mol Pharmacol 79:461–471CrossRefPubMedPubMedCentralGoogle Scholar
  34. Madia PA, Navani DM, Yoburn BC (2011) [(35)S]GTPgammaS binding and opioid tolerance and efficacy in mouse spinal cord. Pharmacol Biochem Behav 101:155–165CrossRefPubMedGoogle Scholar
  35. Maher CE, Eisenach JC, Pan HL, Xiao R, Childers SR (2001) Chronic intrathecal morphine administration produces homologous mu receptor/G-protein desensitization specifically in spinal cord. Brain Res 895:1–8CrossRefPubMedGoogle Scholar
  36. Matthes HW, Maldonado R, Simonin F, Valverde O, Slowe S, Kitchen I, Befort K, Dierich A, Le Meur M, Dollé P, Tzavara E, Hanoune J, Roques BP, Kieffer BL (1996) Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature 383:819–823CrossRefPubMedGoogle Scholar
  37. McNally GP, Akil H (2002) Role of corticotropin-releasing hormone in the amygdala and bed nucleus of the stria terminalis in the behavioral, pain modulatory, and endocrine consequences of opiate withdrawal. Neuroscience 112:605–617CrossRefPubMedGoogle Scholar
  38. Morgan MM, Christie MJ (2011) Analysis of opioid efficacy, tolerance, addiction and dependence from cell culture to human. Br J Pharmacol 164:1322–1334CrossRefPubMedPubMedCentralGoogle Scholar
  39. Morgan MM, Clayton CC, Lane DA (2003) Behavioral evidence linking opioid-sensitive GABAergic neurons in the ventrolateral periaqueductal gray to morphine tolerance. Neuroscience 118:227–232CrossRefPubMedGoogle Scholar
  40. Morgan MM, Clayton CC, Boyer-Quick JS (2005) Differential susceptibility of the PAG and RVM to tolerance to the antinociceptive effect of morphine in the rat. Pain 113:91–98CrossRefPubMedGoogle Scholar
  41. Nestler EJ, Erdos JJ, Terwilliger R, Duman RS, Tallman JF (1989) Regulation of G proteins by chronic morphine in the rat locus coeruleus. Brain Res 476:230–239CrossRefPubMedGoogle Scholar
  42. Nitsche JF, Schuller AG, King MA, Zengh M, Pasternak GW, Pintar JE (2002) Genetic dissociation of opiate tolerance and physical dependence in delta-opioid receptor-1 and preproenkephalin knock-out mice. J Neurosci 22:10906–10913CrossRefPubMedGoogle Scholar
  43. Sanchez-Blazquez P, Garzon J (1994) Antibodies directed against alpha subunits of Gi, Gx/z, GO and GS transducer proteins reduced the morphine withdrawal syndrome in mice. Life Sci 55:PL445–PL450CrossRefPubMedGoogle Scholar
  44. Selley DE, Nestler EJ, Breivogel CS, Childers SR (1997) Opioid receptor-coupled G-proteins in rat locus coeruleus membranes: decrease in activity after chronic morphine treatment. Brain Res 746:10–18CrossRefPubMedGoogle Scholar
  45. Sim LJ, Selley DE, Dworkin SI, Childers SR (1996) Effects of chronic morphine administration on mu opioid receptor-stimulated [35S]GTPgammaS autoradiography in rat brain. J Neurosci 16:2684–2692CrossRefPubMedGoogle Scholar
  46. Sim-Selley LJ, Scoggins KL, Cassidy MP, Smith LA, Dewey WL, Smith FL, Selley DE (2007) Region-dependent attenuation of mu opioid receptor-mediated G-protein activation in mouse CNS as a function of morphine tolerance. Br J Pharmacol 151:1324–1333CrossRefPubMedPubMedCentralGoogle Scholar
  47. Smith PA, Selley DE, Sim-Selley LJ, Welch SP (2007) Low dose combination of morphine and delta9-tetrahydrocannabinol circumvents antinociceptive tolerance and apparent desensitization of receptors. Eur J Pharmacol 571:129–137CrossRefPubMedPubMedCentralGoogle Scholar
  48. Stevens CW, Yaksh TL (1989) Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion. J Pharmacol Exp Ther 250:1–8PubMedGoogle Scholar
  49. Terwilliger RZ, Beitner-Johnson D, Sevarino KA, Crain SM, Nestler EJ (1991) A general role for adaptations in G-proteins and the cyclic AMP system in mediating the chronic actions of morphine and cocaine on neuronal function. Brain Res 548:100–110CrossRefPubMedGoogle Scholar
  50. Traynor JR, Nahorski SR (1995) Modulation by mu-opioid agonists of guanosine-5′-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol 47:848–854PubMedGoogle Scholar
  51. Valeri P, Martinelli B, Pimpinella G, Severini C (1989) Effects of dapiprazole, clonidine and yohimbine on the development of dependence and withdrawal behaviour in mice. Drug Alcohol Depend 23:73–77CrossRefPubMedGoogle Scholar
  52. Wang D, Raehal KM, Lin ET, Lowery JJ, Kieffer BL, Bilsky EJ, Sadee W (2004) Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence. J Pharmacol Exp Ther 308:512–520CrossRefPubMedGoogle Scholar
  53. Wang HY, Friedman E, Olmstead MC, Burns LH (2005) Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbg signaling. Neuroscience 135:247–261CrossRefPubMedGoogle Scholar
  54. Williams JT, Christie MJ, Manzoni O (2001) Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81:299–343CrossRefPubMedGoogle Scholar
  55. Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ (2013) Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 65:223–254CrossRefPubMedPubMedCentralGoogle Scholar
  56. Yaksh TL, Al-Rodhan NR, Jensen TS (1988) Sites of action of opiates in production of analgesia. Prog Brain Res 77:371–394CrossRefPubMedGoogle Scholar
  57. Yoburn BC, Gomes BA, Rajashekara V, Patel C, Patel M (2003) Role of G(i)alpha2-protein in opioid tolerance and mu-opioid receptor downregulation in vivo. Synapse 47:109–116CrossRefPubMedGoogle Scholar
  58. Yu E, Miotto K, Akerele E, Montgomery A, Elkashef A, Walsh R, Montoya I, Fischman MW, Collins J, McSherry F et al (2008) A phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend 97:158–168CrossRefPubMedPubMedCentralGoogle Scholar
  59. Zachariou V, Thome J, Parikh K, Picciotto MR (2000) Upregulation of galanin binding sites and GalR1 mRNA levels in the mouse locus coeruleus following chronic morphine treatments and precipitated morphine withdrawal. Neuropsychopharmacology 23:127–137CrossRefPubMedGoogle Scholar
  60. Zachariou V, Brunzell DH, Hawes J, Stedman DR, Bartfai T, Steiner RA, Wynick D, Langel U, Picciotto MR (2003) The neuropeptide galanin modulates behavioral and neurochemical signs of opiate withdrawal. Proc Natl Acad Sci U S A 100:9028–9033CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany 2017

Authors and Affiliations

  • Jennifer T. Lamberts
    • 1
    • 2
  • Lisa D. Rosenthal
    • 1
  • Emily M. Jutkiewicz
    • 1
  • John R. Traynor
    • 1
  1. 1.Department of Pharmacology and Edward F. Domino Research CenterUniversity of Michigan Medical SchoolAnn ArborUSA
  2. 2.College of PharmacyFerris State UniversityBig RapidsUSA

Personalised recommendations